Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 26Active not recruiting 11Not yet recruiting 10Completed 10Terminated 3Suspended 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Thoracic 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × trastuzumab deruxtecan × Clear all
NCT05744375 2026-04-02

TRANSCENDER

Spanish Breast Cancer Research Group

Phase 2 Terminated
2 enrolled 10 charts
Breast

Breast Neoplasms

NCT03248492 2025-06-26

DESTINY-Breast01

Daiichi Sankyo

Phase 2 Terminated
253 enrolled 21 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03505710 2025-05-30

DESTINY-Lung01

Daiichi Sankyo

Phase 2 Terminated
181 enrolled 17 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡